Implementasi Hukum Waris Islam Di Persatuan Kematian ‎ Al Ikhlas Jl. H. Arief Tembilahan Hulu Tahun 2022‎

 The death association of Al-Ikhlas referred to above is a group of people formed to achieve a common goal. Where the purpose of forming the Al-Ikhlas death association is to help members who are members of it in the event of death. This association provides compensation in the form of funds obtained through the contributions of each member to families who have died in order to make it easier for the family to organize the management of the remains. The Al-Ikhlas Death Association was founded in 2015 which was initiated by one of the religious leaders on Jl. H. Arief Tembilahan Hulu. Untilnow, the Al-Ikhlas death association has 284 members. This research was conducted to understand and examine the implementation of Islamic Inheritance Law in the Al-Ikhlas death association Jln. H. Arief Tembilahan Hulu, 2022. The type of research applied is empirical legal research (socio-legal) or sociological jurisprudence. Based on the results of the research, it was found that in the communion community with the death of Al-Ikhlas Jln. H. Arief Tembilahan Hulu, in 2022 the law of inheritance explains that there is an impact of Islamic inheritance law on the inheritance law of the fellowship of Al-Ikhlas's death Jln. H. Arief Tembilahan Hulu, 2022. Its application in the Al-Ikhlas death fellowship community Jln. H. Arief Tembilahan Hulu, in 2022 he has implemented the provisions contained in the Islamic Inheritance Law.    </jats:p

Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: First results of the PETACC-6 randomized phase III trial.

3531 Background: The PETACC-6 trial investigates whether the addition of oxaliplatin to preoperative oral fluoropyrimidine-based chemoradiation (CRT) followed by postoperative adjuvant fluoropyrimidine-based chemotherapy (CT) improves disease-free survival (DFS) in locally advanced rectal cancer. We present results of the early secondary endpoints. Methods: Between 11/2008 and 09/2011, patients with rectal cancer within 12 cm from the anal verge, T3/4 and/or node-positive, with no evidence of metastatic disease and considered either resectable at the time of entry or expected to become resectable after preoperative CRT, were randomly assigned to receive 5 weeks of preoperative CRT (45 Gy in 25 fractions) with capecitabine (825 mg/m² twice daily), followed by 6 cycles of adjuvant CT with capecitabine (1000 mg/m2twice daily/days 1-15 every three weeks) (arm 1) or to receive the same regimen with the addition of oxaliplatin before (50 mg/m²/days 1, 8, 15, 22, 29) and after surgery (130 mg/m²/day 1, every three weeks) (arm 2). Additional RT before surgery (5.4 Gy/days 36-38) using the same fields or as a boost with capecitabine was an option. Primary endpoint is DFS. Results: 1094 patients were randomized (547 in each arm). 98% and 92% of patients, respectively, received at least 45 Gy of preoperative RT in arm 1 and arm 2. More than 90% of full dose concurrent CT was delivered in 91% and 63% of patients, respectively, in arm 1 and arm 2. Preoperative grade 3/4 toxicity occurred in 15.1% of patients in arm 1 vs. 36.7% in arm 2; 1 vs. 3 patients died before surgery. R0 resection rate was 92.0% in arm 1 and 86.3% in arm 2. The pCR rate (ypT0N0) was equal in both arms with 11.3% in arm 1 and 13.3% in arm 2 (p=0.31). The anal sphincter was preserved in 70% vs. 65% (p=0.09) in arm 1 and 2. Postoperative complications were not different between arms (38% vs. 41%; 5 vs. 4 patients died following surgery). Definitive numbers will be presented at the congress. Conclusions: The addition of oxaliplatin to preoperative fluoropyrimidine-based CRT led to decreased treatment compliance and increased toxicity, but did not improve surgical outcome. Clinical trial information: NCT00766155. </jats:p